Intellia Therapeutics, Inc. reports results for the quarter ended September 30 - Earnings Summary

• Intellia Therapeutics, Inc. reported a quarterly adjusted loss of 91 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -92 cents. The mean expectation of seventeen analysts for the quarter was for a loss of 80 cents per share. Wall Street expected results to range from -89 cents to -72 cents per share.

• Revenue fell 48% to $7.16 million from a year ago; analysts expected $10.46 million.

• Intellia Therapeutics, Inc.'s reported EPS for the quarter was a loss of 91 cents​.

• The company reported a quarterly loss of $127.49 million.

• Intellia Therapeutics, Inc. shares had risen by 2.1% this quarter and gained 36.9% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 0.8% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 9 "strong buy" or "buy," 6 "hold" and 4 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is "buy."

• Wall Street's median 12-month price target for Intellia Therapeutics, Inc. is $16.00, about 23.1% above its last closing price of $12.31

This summary was machine generated from LSEG data November 5 at 03:25 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)